Skip to main content

Table 1 Baseline patient characteristics

From: An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

  pAT (N = 112) AT gamma (N = 110)
Sex Female 51 (45.5) 51 (46.4)
Male 61 (54.5) 59 (53.6)
Age, years Mean ± SD 71.0 ± 15.5 70.4 ± 15.2
< 65 24 (21.4) 34 (30.9)
65 to < 75 34 (30.4) 20 (18.2)
75 to < 85 36 (32.1) 41 (37.3)
≥ 85 18 (16.1) 15 (13.6)
Body weight, kg Mean ± SD 54.3 ± 12.3 53.8 ± 14.0
< 55 57 (50.9) 63 (57.3)
≥ 55 55 (49.1) 47 (42.7)
Bleeding symptoms at baseline Absent 90 (80.4) 93 (84.5)
Present 22 (19.6) 17 (15.5)
DIC score at enrollment Mean ± SD 5.6 ± 1.4 5.6 ± 1.2
< 6 60 (53.6) 62 (56.4)
≥ 6 52 (46.4) 47 (42.7)
SOFA score at enrollment Mean ± SD 8.9 ± 3.7 9.1 ± 3.3
< 10 64 (57.1) 58 (52.7)
≥ 10 47 (42.0) 50 (45.5)
APACHE II score at enrollment Mean ± SD 18.8 ± 6.8 18.2 ± 6.5
< 20 68 (60.7) 61 (55.5)
≥ 20 41 (36.6) 47 (42.7)
AT activity (%) at enrollment (on-site measurement) Mean ± SD 50.9 ± 12.3 51.5 ± 11.6
< 50 43 (38.4) 41 (37.3)
50 to ≤ 70 69 (61.6) 68 (61.8)
Anticoagulant therapy use Gabexate mesylate 22 (19.6) 21 (19.1)
Nafamostat mesylate 6 (5.4) 4 (3.6)
Thrombomodulin 35 (31.3) 34 (30.9)
Heparins 31 (27.7) 32 (29.1)
Replacement therapy use Fresh frozen plasma 24 (21.4) 10 (9.1)
Platelet concentrate 26 (23.2) 22 (20.0)
Any anticoagulant use   83 (74.1) 76 (69.1)
  1. n (%), APACHE acute physiology and chronic health evaluation, AT antithrombin, DIC disseminated intravascular coagulation, pAT plasma-derived antithrombin, SOFA sequential organ failure assessment